DeepMed Research

MASSACHUSETTS GENERAL HOSPITAL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1811-01-01

Employees: -

Market Cap: -

Website: http://www.massgeneral.org/international

Clinical Trials

Niraparib In Recurrent IDH 1/2 Gliomas

Early Phase 1

Recruiting

Conditions: Low-grade Glioma
Glioma, Malignant
IDH2 Gene Mutation
Recurrent Glioma
IDH1 Mutation

Interventions: Drug: Resection/Treatment with Niraparib
Drug: Niraparib

First Posted Date: 2022-06-06

Last Posted Date: 2024-03-29

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 16

Registration Number: NCT05406700

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

PET/MRI in Endometrial Cancer

Not Applicable

Withdrawn

Conditions: Grade 3 Endometrial Endometrioid Adenocarcinoma
High Grade Serous Carcinoma
Endometrial Undifferentiated Carcinoma
Endometrial Mixed Cell Adenocarcinoma
Cytoreductive Surgery

Interventions: Combination Product: PET/MRI with radiotracer ([18F]- fluorodeoxyglucose) and a gadolinium-based contrast agent

First Posted Date: 2022-05-25

Last Posted Date: 2024-04-02

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT05390021

TMS as a Treatment for Apathy in Alzheimer's Disease

Not Applicable

Terminated

Conditions: Alzheimer Disease
Apathy in Dementia

Interventions: Device: Intermittent Theta Burst Stimulation (iTBS)

First Posted Date: 2022-05-25

Last Posted Date: 2025-05-15

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 3

Registration Number: NCT05389644

Locations: 🇺🇸
Martinos Center for Biomedical Imaging/Massachusetts General Hospital, Charlestown, Massachusetts, United States

Multidisciplinary Ventricular Assist Device Clinic

Not Applicable

Conditions: Heart Failure

Interventions: Other: Multidisciplinary team clinic and assessments (Cardiopulmonary exercise test, six-minute-walk-test, MoCA, Quality of Life questionnaires)
Behavioral: Caregiver Self-Assessment

First Posted Date: 2022-05-24

Last Posted Date: 2022-05-24

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 110

Registration Number: NCT05388019

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Therapist-Guided Smartphone-Delivered CBT for MDD

Not Applicable

Completed

Conditions: Major Depressive Disorder

First Posted Date: 2022-05-23

Last Posted Date: 2023-08-14

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 28

Registration Number: NCT05386329

Locations: 🇺🇸
Massachusetts, Boston, Massachusetts, United States

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

Phase 2

Withdrawn

Conditions: Treatment-Resistant Major Depressive Disorder

Interventions: Drug: Psilocybin

First Posted Date: 2022-05-19

Last Posted Date: 2024-01-24

Lead Sponsor: Massachusetts General Hospital

Registration Number: NCT05381974

Locations: 🇺🇸
Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts, United States

A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa

Not Applicable

Recruiting

Conditions: Virologic Failure
HIV Infections
AIDS

Interventions: Other: Individualized Care treatment strategy
Other: Immediate Switch
Other: Standard of Care treatment strategy

First Posted Date: 2022-05-13

Last Posted Date: 2025-03-05

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 648

Registration Number: NCT05373758

Locations: 🇿🇦
RK Khan Hospital Clinic, Durban, South Africa
🇺🇬
Mbarara Regional Referral Hospital Immune Suppression Syndrome Clinic, Mbarara, Uganda
🇺🇬
Mbarara City Clinic, Mbarara, Uganda

Managing Pain and Cognitions in Older Adults With Early Cognitive Decline and Chronic Pain

Not Applicable

Recruiting

Conditions: Physical Activity
Chronic Pain
Mild Cognitive Impairment
Older Adults

Interventions: Behavioral: Active Brains 1
Behavioral: Active Brains 2

First Posted Date: 2022-05-13

Last Posted Date: 2023-03-03

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 260

Registration Number: NCT05373745

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Varenicline for Nicotine Vaping Cessation in Adolescents

Phase 4

Completed

Conditions: Vaping
Nicotine Dependence

Interventions: Drug: Double Blind Varenicline
Drug: Double Blind Placebo
Behavioral: QuitVaping
Behavioral: This Is Quitting

First Posted Date: 2022-05-10

Last Posted Date: 2025-04-27

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 261

Registration Number: NCT05367492

Locations: 🇺🇸
Center for Addiction Medicine, Boston, Massachusetts, United States

Peripheral Neuroimmune Mechanisms of Hyperthermia

Not Applicable

Recruiting

Conditions: Major Depressive Disorder
Hyperthermia
Inflammation

Interventions: Device: Sham
Device: WBH

First Posted Date: 2022-05-09

Last Posted Date: 2023-03-10

Lead Sponsor: Massachusetts General Hospital

Target Recruit Count: 60

Registration Number: NCT05366270

Locations: 🇺🇸
Massachusetts General Hospital Depression Clinical & Research Program, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy